Отображение 1 - 2 результаты of 2 для поиска 'on behalf of the FUTURE 2 Study Group', время запроса: 0.02сек. Отмена результатов
  1. 1
    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study по Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group

    Опубликовано 2018-06-01
    Полный текст
    Статья
  2. 2
    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... по L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group

    Опубликовано 2018-12-01
    Полный текст
    Статья

Инструменты поиска: